BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Down 79.5% in July

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 190,323 shares, a drop of 79.5% from the June 30th total of 929,023 shares. Based on an average trading volume of 8,831,855 shares, the short-interest ratio is presently 0.0 days. Approximately 1.6% of the shares of the company are short sold.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new position in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX at the end of the most recent reporting period. Hedge funds and other institutional investors own 40.57% of the company’s stock.

BiomX Stock Performance

Shares of NYSEAMERICAN:PHGE traded up $0.01 during trading hours on Monday, hitting $0.20. The stock had a trading volume of 859,175 shares, compared to its average volume of 4,014,839. BiomX has a 1-year low of $0.18 and a 1-year high of $13.70. The firm has a market capitalization of $2.33 million, a price-to-earnings ratio of -0.06 and a beta of 1.30. The stock’s fifty day simple moving average is $0.55 and its 200 day simple moving average is $2.61.

BiomX (NYSEAMERICAN:PHGE) last announced its earnings results on Wednesday, May 20th. The company reported $7.38 earnings per share for the quarter. As a group, research analysts anticipate that BiomX will post -5.85 EPS for the current year.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.